# Propanc Biopharma, Inc. (PPCB)

> Source: Nexqual · https://nexqual.com/PPCB · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Propanc Biopharma, Inc. (PPCB), nexqual.com/PPCB" · informational, not investment advice.

**Price:** USD 0.34 (-6.62% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.37 · day 0.33–0.37 · 52w 0.33–41.25 · market cap $3.4M · NCM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -99.1% vs S&P 500 +18.1%; 5Y -100.0% vs S&P 500 +85.1%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$2.0M | -$1.8M | -$1.5M | -$57.3M | -$18.2M | -$18.2M |
| Net income | -$2.7M | -$2.7M | -$1.8M | -$58.9M | -$18.9M | -$18.9M |
| EPS (diluted) | -$2461.50 | -$90.00 | -$35513.25 | -$371.22 | -$17.62 | — |
| Free cash flow | — | — | — | — | -$5.7M | -$5.7M |
| Cash + short-term investments | $4K | $10K | $21K | $12K | $832K | — |
| Total debt | $926K | $391K | $399K | $538K | — | — |
Fiscal years end Jun. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 0.4x · FCF yield -169.41% · Earnings yield -561.84%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -99.1% | -100.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -99.2% | -81.0% |
| Volatility (annualized) | 159.6% | 477.7% |
| Max drawdown | -99.2% (Oct 2025→Oct 2026) | -100.0% (Dec 2021→Dec 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/PPCB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt